Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients

@article{Esposito2012ProportionOP,
  title={Proportion of patients at HbA1c target <7\% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients},
  author={Katherine Esposito and Paolo Chiodini and Giuseppe Bellastella and Maria Ida Maiorino and Dario Giugliano},
  journal={Diabetes},
  year={2012},
  volume={14}
}
Aim: We assessed the efficacy of eight classes of diabetes medications used in current clinical practice [metformin, sulphonylureas, α‐glucosidase inhibitors, thiazolidinediones, glinides, dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 (GLP‐1) analogues and insulin analogues] to reach the HbA1c target <7% in type 2 diabetes. 
View on Wiley
ncbi.nlm.nih.gov
131 Citations
Highly Influential Citations
5
Background Citations
35
Methods Citations
6
Results Citations
6

131 Citations

Citation Type

Citation Type

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis
TLDR
This systematic review and meta‐analysis was to assess effect of linagliptin on glycaemic control, biomarkers and incidence of adverse events in patients with type 2 diabetes mellitus.
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post‐marketing study (J‐STEP/EL Study)
TLDR
A 1‐year post‐marketing study of tofogliflozin, a novel agent in this class of sodium‐glucose cotransporter 2 inhibitors, in Japanese elderly patients with type 2 diabetes mellitus found it to be a safe and effective treatment for these patients.
Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes.
Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.
Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)
The present study analysis was carried out to evaluate the safety and efficacy of tofogliflozin, a sodium–glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus in…
Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study
TLDR
For adults with T2D inadequately controlled on OADs, this analysis reveals an unmet clinical need and suggests that in individuals with baseline HbA1c ≥ 9.0%, only a minority are likely to achieve an Hb a1c above target with a GLP-1 RA or BI alone.
Free and fixed‐ratio combinations of basal insulin and GLP‐1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
TLDR
Combination strategies, either free or fixed, represent a good option for intensifying basal insulin therapy in patients with type 2 diabetes who need amelioration of glycaemic control.
Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin
In Brief For patients with type 2 diabetes who require add-on therapy to metformin plus basal insulin, GLP-1 receptor agonists may be a favorable option because they effectively manage postprandial…
Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors
TLDR
The HbA1c response to DPP-4 inhibitors can be modulated mainly by baseline Hb a1c and fasting glucose levels: a greater absolute reduction of baseline Ha1c is seen in patients with higher baseline H bA 1c and lower fasting glucose level.
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
  • H. Rodbard, P. Jellinger, +9 authors S. Schwartz
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2009
TLDR
An algorithm to assist primary care physicians, endocrinologists, and others in the management of adult, nonpregnant patients with type 2 diabetes mellitus to achieve a hemoglobin A1c of 6.5% or less is presented, with recognition of the need for individualization to minimize the risks of hypoglycemia.
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
TLDR
This revision of the consensus algorithm for the medical management of type 2 diabetes focuses on the new classes of medications that now have more clinical data and experience and addresses safety issues surrounding the thiazolidinediones.
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes
TLDR
This work has shown that in clinical trials aimed at normoglycemia and achieving a mean A1C of ∼7%, severe hypoglycemic episodes occurred at a rate of between 1 and 3 per 100 patient-years, which is not a balanced description of the published literature.
Executive Summary: Standards of Medical Care in Diabetes—2011
  • Medicine
    Diabetes Care
  • 2011
TLDR
Current criteria for the diagnosis of diabetes c A1C $6.5% ; c in the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing.
National trends in treatment of type 2 diabetes mellitus, 1994-2007.
TLDR
Increasing use of glitazones, newer insulins, sitagliptin phosphate, and exenatide largely accounted for recent increases in the mean cost per prescription and aggregate drug expenditures.
Baseline Quality-of-Care Data From a Quality-Improvement Program Implemented by a Network of Diabetes Outpatient Clinics
TLDR
This study is the first step of a nationwide quality-improvement effort and documents the possibility of obtaining standardized information to be used for diabetes care profiling and benchmarking activities at the national level.
Executive Summary: Standards of Medical Care in Diabetes—2008
  • Medicine
    Diabetes Care
  • 2008
These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to…
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Advanced methods in meta-analysis: multivariate approach and meta-regression.
This tutorial on advanced statistical methods for meta-analysis can be seen as a sequel to the recent Tutorial in Biostatistics on meta-analysis by Normand, which focused on elementary methods.…
...
1
2
...